Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A prospective, controlled, open trial in psoriasis patients with metabolic syndrome,
candidate to methotrexate or secukinumab was conducted between January 2019 and May 2020. The
primary end point of the study was investigating any variations in waist circumference, body
mass index (BMI), blood pressure, fasting glucose, total cholesterol, low density lipoprotein
(LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), creatinine levels between baseline
and month-6 and 12 of follow-up.